Jeffrey M. Gelfand

16.6k total citations · 1 hit paper
110 papers, 4.8k citations indexed

About

Jeffrey M. Gelfand is a scholar working on Pathology and Forensic Medicine, Neurology and Molecular Biology. According to data from OpenAlex, Jeffrey M. Gelfand has authored 110 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pathology and Forensic Medicine, 30 papers in Neurology and 15 papers in Molecular Biology. Recurrent topics in Jeffrey M. Gelfand's work include Multiple Sclerosis Research Studies (40 papers), Peripheral Neuropathies and Disorders (18 papers) and Autoimmune Neurological Disorders and Treatments (15 papers). Jeffrey M. Gelfand is often cited by papers focused on Multiple Sclerosis Research Studies (40 papers), Peripheral Neuropathies and Disorders (18 papers) and Autoimmune Neurological Disorders and Treatments (15 papers). Jeffrey M. Gelfand collaborates with scholars based in United States, United Kingdom and Switzerland. Jeffrey M. Gelfand's co-authors include Ari Green, Bruce Cree, Stephen L. Hauser, Rachel Nolan, Carolyn Bevan, Sarosh R. Irani, Michael D. Geschwind, Jennifer Graves, Riley Bove and A. J. Green and has published in prestigious journals such as The Lancet, The Journal of Experimental Medicine and The Journal of Cell Biology.

In The Last Decade

Jeffrey M. Gelfand

101 papers receiving 4.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial

2017 393 citations Ari Green, Jeffrey M. Gelfand et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey M. Gelfand United States	38	1.7k	1.7k	823	787	600	110	4.8k
Desmond P. Kidd United Kingdom	33	1.5k 0.9×	2.3k 1.3×	561 0.7×	716 0.9×	845 1.4×	75	4.8k
Orhun H. Kantarci United States	37	1.6k 0.9×	2.7k 1.6×	1.1k 1.4×	489 0.6×	973 1.6×	133	4.8k
Aksel Sıva Türkiye	45	1.9k 1.1×	2.8k 1.6×	503 0.6×	1.9k 2.4×	1.3k 2.1×	173	6.1k
Ellen M. Mowry United States	42	1.4k 0.8×	3.8k 2.2×	978 1.2×	212 0.3×	749 1.2×	152	5.6k
Steven E. Feldon United States	37	1.6k 0.9×	1.6k 0.9×	706 0.9×	1.7k 2.1×	201 0.3×	134	4.7k
Jonathan D. Trobe United States	35	2.0k 1.2×	1.5k 0.9×	331 0.4×	1.5k 1.9×	339 0.6×	212	4.3k
Tania Kümpfel Germany	40	2.2k 1.3×	3.6k 2.1×	1.3k 1.6×	260 0.3×	936 1.6×	151	6.3k
Eoin P. Flanagan United States	47	5.9k 3.4×	3.6k 2.1×	1.1k 1.3×	467 0.6×	1.3k 2.2×	296	8.2k
Simmons Lessell United States	38	1.9k 1.1×	911 0.5×	697 0.8×	1.8k 2.2×	413 0.7×	183	4.6k
Christine Lebrun‐Frénay France	42	2.1k 1.2×	3.5k 2.0×	822 1.0×	178 0.2×	957 1.6×	268	5.8k

Countries citing papers authored by Jeffrey M. Gelfand

Since Specialization

Citations

This map shows the geographic impact of Jeffrey M. Gelfand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey M. Gelfand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey M. Gelfand more than expected).

Fields of papers citing papers by Jeffrey M. Gelfand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey M. Gelfand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey M. Gelfand. The network helps show where Jeffrey M. Gelfand may publish in the future.

Co-authorship network of co-authors of Jeffrey M. Gelfand

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey M. Gelfand. A scholar is included among the top collaborators of Jeffrey M. Gelfand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey M. Gelfand. Jeffrey M. Gelfand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

LaHue, Sara C., Sharon A. Chung, Riley Bove, et al.. (2025). Biopsy-Confirmed Small Vessel Primary CNS Vasculitis. Neurology Neuroimmunology & Neuroinflammation. 12(4). e200397–e200397.

Guo, Chu‐Yueh, et al.. (2025). Actionable Wearables Data for the Neurology Clinic: A Proof‐of‐Concept Tool. Annals of Clinical and Translational Neurology. 12(8). 1556–1565.

Waldrop, Greer, Samuel J. Pleasure, Michael R. Wilson, et al.. (2025). Neutropenia Associated With B Cell–Depleting Therapies in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Neurology Neuroimmunology & Neuroinflammation. 12(4). e200430–e200430. 2 indexed citations

Hu, Tiffany, Javier Rodríguez, Lara Zimmermann, et al.. (2025). Complement Factor I Deficiency With Acute Hemorrhagic Leukoencephalitis and Longitudinally Extensive Transverse Myelitis. Neurology Neuroimmunology & Neuroinflammation. 12(6). e200475–e200475.

Abboud, Hesham, Stacey Clardy, Divyanshu Dubey, et al.. (2025). The Clinical Trial Landscape in Autoimmune Encephalitis. Neurology. 104(8). e213487–e213487. 4 indexed citations

Bove, Riley, et al.. (2024). Low Referral Rates for Pelvic Floor Physical Therapy in MS Patients with Bladder Dysfunction: An Opportunity to Close the Gap. Multiple Sclerosis and Related Disorders. 86. 105592–105592. 1 indexed citations

Bartley, Christopher M., Thomas Ngo, Cathryn R. Cadwell, et al.. (2023). Dual ankyrinG and subpial autoantibodies in a man with well-controlled HIV infection with steroid-responsive meningoencephalitis: A case report. Frontiers in Neurology. 13. 1102484–1102484. 5 indexed citations

Block, Valerie J., Kanishka Koshal, Jeffrey M. Gelfand, et al.. (2023). A Closed-Loop Falls Monitoring and Prevention App for Multiple Sclerosis Clinical Practice: Human-Centered Design of the Multiple Sclerosis Falls InsightTrack. JMIR Human Factors. 11. e49331–e49331. 6 indexed citations

Gelfand, Jeffrey M., et al.. (2023). Fall Assessment and Monitoring in People With Multiple Sclerosis. Neurology Clinical Practice. 13(5). e200184–e200184. 6 indexed citations

10.

Block, Valerie J., Richard Cuneo, Gina Kirkish, et al.. (2022). Association of daily physical activity with brain volumes and cervical spinal cord areas in multiple sclerosis. Multiple Sclerosis Journal. 29(3). 363–373. 9 indexed citations

11.

Brown, E. Sherwood, et al.. (2021). Glucocorticoids for therapeutic immunosuppression: Clinical pearls for the practicing neurologist. Journal of the Neurological Sciences. 430. 120004–120004. 21 indexed citations

12.

Hua, Le H., Ahmed Z. Obeidat, Lilyana Amezcua, et al.. (2021). Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology. Neurology Clinical Practice. 11(4). 352–357. 2 indexed citations

13.

Block, Valerie J., Erica Pitsch, Chao Zhao, et al.. (2021). Identifying Falling Risk Factors Remotely in Multiple Sclerosis (2597). Neurology. 96(15_supplement). 1 indexed citations

14.

Guo, Chu‐Yueh, Jeffrey M. Gelfand, & Michael D. Geschwind. (2020). Anti-gamma-aminobutyric acid receptor type A encephalitis: a review. Current Opinion in Neurology. 33(3). 372–380. 15 indexed citations

15.

Turcotte, Justin, et al.. (2020). Opioid Prescribing Guidelines for Arthroscopic Partial Meniscectomy Based on Patient-reported Opioid Consumption.. Journal of Surgical Orthopaedic Advances. 29(4). 240–243. 1 indexed citations

16.

Rowles, William, Antoine Lizée, Arno Klein, et al.. (2020). A Precision Medicine Tool for Patients With Multiple Sclerosis (the Open MS BioScreen): Human-Centered Design and Development. Journal of Medical Internet Research. 22(7). e15605–e15605. 22 indexed citations

17.

Stern, Barney J., Walter Royal, Jeffrey M. Gelfand, et al.. (2018). Definition and Consensus Diagnostic Criteria for Neurosarcoidosis. JAMA Neurology. 75(12). 1546–1546. 198 indexed citations

18.

Gelfand, Jeffrey M., Carolyn Fredericks, Matteo Paoletti, et al.. (2016). Development of a Diagnostic Decision Tree for Rapidly Progressive Dementia (P5.182). Neurology. 86(16_supplement). 2 indexed citations

19.

Höftberger, Romana, Agnes van Sonderen, Frank Leypoldt, et al.. (2015). Encephalitis and AMPA receptor antibodies. Neurology. 84(24). 2403–2412. 243 indexed citations

20.

Schlaeger, Regina, Nico Papinutto, Valentina Panara, et al.. (2014). Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Annals of Neurology. 76(4). 568–580. 143 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact